Deciphera Pharmaceuticals, Inc. to Present at the 2019 Cantor Global Healthcare Conference
September 25 2019 - 7:00AM
Business Wire
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage
biopharmaceutical company focused on addressing key mechanisms of
tumor drug resistance, today announced that Steve Hoerter,
President and Chief Executive Officer, will present at the 2019
Cantor Global Healthcare Conference on Wednesday, October 2 at 9:30
AM ET in New York City.
A live webcast of the event will be available on the “Events and
Presentations” page in the “Investors” section of the Company’s
website at
https://investors.deciphera.com/news-events/events-presentations. A
replay of the webcast will be archived on the Company’s website for
90 days following the presentation.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients by
tackling key mechanisms of drug resistance that limit the rate
and/or durability of response to existing cancer therapies. Our
small molecule drug candidates are directed against an important
family of enzymes called kinases, known to be directly involved in
the growth and spread of many cancers. We use our deep
understanding of kinase biology together with a proprietary
chemistry library to purposefully design compounds that maintain
kinases in a “switched off” or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed
to address therapeutic resistance causing mutations and
immuno-targeted agents designed to control the activation of
immunokinases that suppress critical immune system regulators, such
as macrophages. We have used our platform to develop a diverse
pipeline of tumor-targeted and immuno-targeted drug candidates
designed to improve outcomes for patients with cancer by improving
the quality, rate and/or durability of their responses to
treatment.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190925005175/en/
Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc.
jrobinson@deciphera.com 781-906-1112
Media: David Rosen Argot Partners
David.Rosen@argotpartners.com 212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Sep 2023 to Sep 2024